Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › Biotheranostics Settles False Claims Allegations With DOJ for $2M

Biotheranostics Settles False Claims Allegations With DOJ for $2M

Apr 20, 2018
|
staff reporter

NEW YORK (GenomeWeb) – The US Department of Justice said on Thursday that Biotheranostics has agreed to pay $2 million to settle allegations that the company improperly billed Medicare for molecular breast cancer tests. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Aug
19
Featured Webinar

Case Study: An IVD Manufacturer’s Experience Building a Complete Sample-to-Result Workflow

Sponsored by
UgenTec

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.

What's Popular?

In Cancer

  1. Natera's Signatera ctDNA Test Shows Immunotherapy Response Prediction Capability in Advanced Cancer

  2. Exact Sciences Positions Itself as Cancer Testing Provider of Future as COVID Crisis Continues

    Premium

  3. Todos Medical, Pathnova Partner on Breast Cancer, SARS-CoV-2 Tests

  4. Oncocyte Provides Post-Mortem on DetermaDx Failure, Describes Renewed Focus on Remaining Assays

    Premium

  5. SARS-CoV-2 Testing Drives Opko Health Q2 Revenues Up 33 Percent

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.